Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Are you taking FDA-unapproved drugs without knowing it?

Martha Rosenberg
Meds
November 6, 2024
Share
Tweet
Share

If you think the labyrinth of U.S. government agencies and congressional subcommittees is complicated, be grateful you are not a pharmacy owner! Just to get your drugs reimbursed, you must navigate a river of upstream, midstream, and downstream suppliers, health plans and insurers, employers and other payers (including federal and state governments), rebate aggregators, “white and brown baggers,” and an alphabet soup of entities/concepts called things like PSAOs, GPOs, NADACs, ASOs, MLRs, AWPs, WACs, U&Cs, MACs, BERs, GERs, DFERs, GDRs, NDCs, DIRs, and ERISAs.

Many have not heard of pharmacy benefit managers (PBM), but much of the news about pharmacies today centers on their widening role and control of almost 80 percent of U.S. processed prescriptions. PBMs provide formulary development, pharmacy network design, and drug utilization management, but a growing chorus of pharmacists, patient advocates, lawmakers, and private and public watchdogs accuse them of inflating drug prices, limiting drug choices, steering patients to remunerating pharmacies (“self-dealing”), and reducing competition.

Pharmacies often do not know the amount they will be reimbursed by PBMs, the “big three” of which are CVS Caremark, Express Scripts, and OptumRx, and even operate at a loss. Several states have enacted PBM reform laws that include:

  1. “Duty of care” requirements (putting patients first)
  2. Limits on PBM “spread pricing” (paying pharmacies less than plan sponsors are charged)
  3. Transparency (disclosing rebate, mail order, offshore “rebate aggregator” and other profit centers)
  4. Prohibitions on discrimination against unaffiliated pharmacies
  5. Limiting patient co-pays charged by PBMs

Similar federal legislation is pending.

I recently spoke with Bill Nulman, a 28-year pharmacy benefit industry veteran, about the problem of illegal FDA-unapproved medications. Coverage of these medications is widespread in formularies and in pharmacy utilization, regardless of client size, type, or location, and creates patient health and safety risks, plan sponsor fiduciary and financial risks, and multiple risks to dispensing pharmacies, says Nulman.

MR: Please tell me about the FDA-unapproved drug problem.

BN: PBMs and insurance carriers standardly charge plan sponsors and patients for FDA-unapproved medications without the required FDA-issued NDAs (new drug applications), ANDAs (abbreviated NDAs), or BLAs (biologics license applications). Most PBM contracts include the term “FDA approved,” so PBMs and carriers that process and charge for FDA-unapproved medications are often in direct violation of the plan sponsor contract. For PBMs that own mail-order facilities, violations of state boards of pharmacy regulations and state laws occur. The OIG (Office of Inspector General) has confirmed the issue, and CMS (Centers for Medicare & Medicaid Services) concurs with their resolutions. The FDA has published that one to two percent of all prescriptions are unapproved, and the following:

  • Inclusion in the NDC (national drug code) directory does not indicate that FDA has verified the information provided or that the products are FDA approved. The content of each NDC directory entry is the responsibility of the labeler submitting the SPL (structured product labeling) file.
  • Assignment of an NDC number does not denote FDA approval of the product. Such impressions are misleading and violate federal law.
  • Inclusion in the NDC directory or assignment of an NDC number does not mean a product is a drug as defined by federal law or covered or eligible for reimbursement by Medicare, Medicaid, or other payers.

MR: How does this happen?

BN: It is not a complex process for a manufacturer to apply for and obtain a labeler code, which is the first five digits of a drug’s NDC. Drugmakers can then submit products into the national drug databases, and claims for these drugs will adjudicate, be charged to plan sponsors and patients, and be dispensed, regardless of their FDA approval status.

Whether it’s a state Medicaid plan or a small or large commercial plan sponsor, FDA-unapproved drugs are found 100 percent of the time.

MR: Why doesn’t the FDA stop this?

BN: The FDA has no access to data and does not validate the information submitted by manufacturers into national drug databases.

MR: Doctors prescribe such drugs and patients take them?

ADVERTISEMENT

BN: If the doctor writes a prescription for an FDA-unapproved drug and the pharmacy fills it, then that claim will process––the plan sponsor and patient will pay––and no one shall be the wiser. PBMs and insurance carriers should be creating formularies with legal, safe, and effective drugs, which is required by the federal Food, Drug, and Cosmetic Act.

MR: Aren’t there penalties?

BN: Yes. Each state has a board of pharmacy that governs licensed pharmacies, and there are specific and applicable state laws and regulations, including from the federal act––anything from license suspension and license revocation to civil and criminal fines. One goal is to support pharmacies and eliminate their risk and exposure.

MR: Can you give examples of unapproved drugs?

BN: Examples start with NP Thyroid, phenobarbital, and many prenatal vitamins and dietary supplements. There are thousands more across many therapeutic drug classes. There is a prevalence of unapproved dietary supplements billed to plan sponsors for $1,200–$3,300 per month, for example.

MR: In September, Pharmacists United for Truth and Transparency (PUTT), Minnesota Independent Pharmacies, and four other groups demonstrated in front of the Eden Prairie, MN, headquarters of UnitedHealth, whose PBM is OptumRx. What factors drove this demonstration?

BN: More pharmacies, especially independents, have closed this year than in any other year. From what I have read, contributing factors include lower reimbursement rates, clawbacks, and various fees. There has also been an increase in PBM-owned retail, mail order, and specialty pharmacy utilization, diverting prescriptions from independent pharmacies.

MR: How big are the risks from this situation?

BN: The problem of FDA-unapproved drugs is universal, and the risks from coverage influence the entire life cycle of a prescription, from prescribing by physicians to claim adjudication, to plan sponsors’ payments, to pharmacy dispensing, and most importantly, to consumption by patients unknowingly.

Martha Rosenberg is a health reporter and the author of Big Food, Big Pharma, Big Lies and Born With a Junk Food Deficiency.  

Prev

Is staying worth it? How one physician broke free from the "sunk cost fallacy" [PODCAST]

November 5, 2024 Kevin 0
…
Next

Sick and tired of practicing medicine? Burnout, disappointment, and low income you can’t seem to overcome?

November 6, 2024 Kevin 0
…

Tagged as: Medications

Post navigation

< Previous Post
Is staying worth it? How one physician broke free from the "sunk cost fallacy" [PODCAST]
Next Post >
Sick and tired of practicing medicine? Burnout, disappointment, and low income you can’t seem to overcome?

ADVERTISEMENT

More by Martha Rosenberg

  • How drugmakers manipulate your health from diagnosis to prescription

    Martha Rosenberg
  • Conflicts of interest are eroding trust in U.S. health agencies

    Martha Rosenberg
  • How drug companies turned “depression” into a billion-dollar industry

    Martha Rosenberg

Related Posts

  • It is time for the FDA to re-evaluate metrics for weight loss drugs

    Tatum R. Dam, Diana A. Hla, Aditya Narayan, and Ank A. Agarwal
  • The ritual of taking medications: the pill wheel

    Fery Pashang, PharmD
  • The FDA was wrong about Aduhelm

    M. Bennet Broner, PhD
  • Are you storing your medications wrong?

    Dr. Farees Ahmad Khan & Dr. Sarah Alnaher
  • Counterfeit drugs: a hidden danger lurking in your medicine cabinet

    Emily Kahoud
  • Does the FDA approval of aducanumab mark the return of science-based medicine?

    Robert Trent

More in Meds

  • How medicine repurposing enables value-based pain management and insomnia therapy

    Olumuyiwa Bamgbade, MD
  • Forced voicemail and diagnosis codes are endangering patient access to medications

    Arthur Lazarus, MD, MBA
  • From stigma to science: Rethinking the U.S. drug scheduling system

    Artin Asadipooya
  • How drugmakers manipulate your health from diagnosis to prescription

    Martha Rosenberg
  • The food-drug interaction risks your doctor may be missing

    Frank Jumbe
  • Why retail pharmacies are the future of diverse clinical trials

    Shelli Pavone
  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Why ADHD in women requires a new approach [PODCAST]

      The Podcast by KevinMD | Podcast
    • AI is already replacing doctors—just not how you think

      Bhargav Raman, MD, MBA | Tech
    • Why doctors must stop ignoring unintentional weight loss in patients with obesity

      Samantha Malley, FNP-C | Conditions
    • Why more doctors are choosing direct care over traditional health care

      Grace Torres-Hodges, DPM, MBA | Physician
    • Why hospitals are quietly capping top doctors’ pay

      Dennis Hursh, Esq | Conditions
    • Why point-of-care ultrasound belongs in emergency department triage

      Resa E. Lewiss, MD and Courtney M. Smalley, MD | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Why ADHD in women requires a new approach [PODCAST]

      The Podcast by KevinMD | Podcast
    • AI is already replacing doctors—just not how you think

      Bhargav Raman, MD, MBA | Tech
    • Why doctors must stop ignoring unintentional weight loss in patients with obesity

      Samantha Malley, FNP-C | Conditions
    • Why more doctors are choosing direct care over traditional health care

      Grace Torres-Hodges, DPM, MBA | Physician
    • Why hospitals are quietly capping top doctors’ pay

      Dennis Hursh, Esq | Conditions
    • Why point-of-care ultrasound belongs in emergency department triage

      Resa E. Lewiss, MD and Courtney M. Smalley, MD | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...